BCL2 and Thrombocytopenia: As a consequence, thrombocytopenia is a common adverse effect of BH3‐mimetics, resulting from the antagonism of BCL‐xL, the primary platelet prosurvival protein belonging to the BCL‐2 family, which serves to impede apoptosis in a BAK/BAX‐dependent manner [33].